249 related articles for article (PubMed ID: 30317416)
21. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
22. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
24. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study.
Bhardwaj A; Rehman SU; Mohammed AA; Gaggin HK; Barajas L; Barajas J; Moore SA; Sullivan D; Januzzi JL
Am Heart J; 2012 Nov; 164(5):793-799.e1. PubMed ID: 23137512
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).
Sanders-van Wijk S; van Asselt AD; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Vuillomenet A; Peter M; Pfisterer ME; Brunner-La Rocca HP;
JACC Heart Fail; 2013 Feb; 1(1):64-71. PubMed ID: 24621800
[TBL] [Abstract][Full Text] [Related]
27. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
28. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
29. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
30. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
31. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
Weaver FA; Abraham WT; Little WC; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Madershahian N; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Zile MR
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):320-328. PubMed ID: 28043438
[TBL] [Abstract][Full Text] [Related]
32. Devices for Autonomic Regulation Therapy in Heart Failure With Reduced Ejection Fraction.
Wagner BR; Frishman WH
Cardiol Rev; 2018; 26(1):43-49. PubMed ID: 29045291
[TBL] [Abstract][Full Text] [Related]
33. Oral Chinese Herbal Medicine for Heart Failure with Preserved Ejection Fraction: A Meta-Analysis.
Mei J; Xu H; Xu FQ; Ju JQ
Chin J Integr Med; 2019 Oct; 25(10):770-777. PubMed ID: 31127505
[TBL] [Abstract][Full Text] [Related]
34. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
35. Exercise-based cardiac rehabilitation in patients with reduced left ventricular ejection fraction: The Cardiac Rehabilitation Outcome Study in Heart Failure (CROS-HF): A systematic review and meta-analysis.
Bjarnason-Wehrens B; Nebel R; Jensen K; Hackbusch M; Grilli M; Gielen S; Schwaab B; Rauch B;
Eur J Prev Cardiol; 2020 Jun; 27(9):929-952. PubMed ID: 31177833
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of baroreflex activation therapy for heart failure: A meta-analysis of randomized controlled trials.
Cai G; Guo K; Zhang D; Qin S
Medicine (Baltimore); 2020 Nov; 99(45):e22951. PubMed ID: 33157936
[TBL] [Abstract][Full Text] [Related]
37. Catheter Ablation Versus Medical Therapy for Atrial Fibrillation in Patients With Heart Failure: A Meta-Analysis of Randomised Controlled Trials.
Virk SA; Bennett RG; Chow C; Sanders P; Kalman JM; Thomas S; Kumar S
Heart Lung Circ; 2019 May; 28(5):707-718. PubMed ID: 30509786
[TBL] [Abstract][Full Text] [Related]
38. Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure.
Zhou X; Xu W; Xu Y; Qian Z
Am J Med; 2019 Aug; 132(8):955-963. PubMed ID: 30853478
[TBL] [Abstract][Full Text] [Related]
39. Quality of life questionnaire predicts poor exercise capacity only in HFpEF and not in HFrEF.
Ahmeti A; Henein MY; Ibrahimi P; Elezi S; Haliti E; Poniku A; Batalli A; Bajraktari G
BMC Cardiovasc Disord; 2017 Oct; 17(1):268. PubMed ID: 29041912
[TBL] [Abstract][Full Text] [Related]
40. Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction.
Karavidas A; Driva M; Parissis JT; Farmakis D; Mantzaraki V; Varounis C; Paraskevaidis I; Ikonomidis I; Pirgakis V; Anastasiou-Nana M; Filippatos G
Am Heart J; 2013 Oct; 166(4):760-7. PubMed ID: 24093858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
